Olema Pharmaceuticals, Inc. (OLMA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA® (darolutamide) in Metastatic Castration-Resistant Prostate Cancer
Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting
Olema Oncology to Participate in Upcoming Investor Conferences
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Oncology Appoints Prakash Raman, Ph.D., to Board of Directors
Olema Oncology to Present Initial Clinical Data for OP-3136 at the 2026 ASCO Annual Meeting
Analyzing Olema Pharmaceuticals (NASDAQ:OLMA) and Ligand Pharmaceuticals (NASDAQ:LGND)
SG Americas Securities LLC Purchases Shares of 69,382 Olema Pharmaceuticals, Inc. $OLMA
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Stock Up 242%, but Does a $122 Million Position Suggest More Upside Potential?
Olema Pharmaceuticals (OLMA) Loses 33.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Biotech Stock Up Nearly 300% Draws $68.7 Million Bet as Breast Cancer Drug Targets 2027 Launch
Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
Olema Pharmaceuticals, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – OLMA
Why Is Olema Pharmaceuticals Stock Dropping On Monday?
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Pharmaceuticals, Inc. (OLMA) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript
Olema Pharmaceuticals CEO Teases Fall OPERA-01 Readout, Q2 KAT6 Data and CFO/COO Exit
Olema Pharmaceuticals, Inc. (OLMA) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript
Olema Oncology to Participate in Upcoming Investor Conferences
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Oncology Announces Departure of Chief Operating and Financial Officer
Campbell & CO Investment Adviser LLC Buys New Shares in Olema Pharmaceuticals, Inc. $OLMA
Olema Pharmaceuticals (NASDAQ:OLMA) Director Cyrus Harmon Sells 3,489 Shares
Olema Pharmaceuticals, Inc. (OLMA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Receives Consensus Rating of “Moderate Buy” from Brokerages
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Oncology to Present at 44th Annual J.P. Morgan Healthcare Conference
Insider Selling: Olema Pharmaceuticals (NASDAQ:OLMA) Director Sells $82,194.93 in Stock
David Myles Sells 51,000 Shares of Olema Pharmaceuticals (NASDAQ:OLMA) Stock
Naseem Zojwalla Sells 70,000 Shares of Olema Pharmaceuticals (NASDAQ:OLMA) Stock
Ian Clark Sells 264,800 Shares of Olema Pharmaceuticals (NASDAQ:OLMA) Stock
Naseem Zojwalla Sells 99,509 Shares of Olema Pharmaceuticals (NASDAQ:OLMA) Stock
Naseem Zojwalla Sells 100,000 Shares of Olema Pharmaceuticals (NASDAQ:OLMA) Stock
Olema: 'Strong Buy' Maintained On OPERA-02 Trial Initiation & Additional Shots On Goal
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Given Consensus Recommendation of “Moderate Buy” by Brokerages
Olema Oncology to Participate in 8th Annual Evercore Healthcare Conference
Olema Oncology Announces Closing of $218.5 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
Olema Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:OLMA)
Olema Oncology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Pharma Bro Martin Shkreli Shorts Olema Pharmaceuticals Stock
Cancer Focused Olema Pharmaceuticals Stock Soars 150% - Here's Why
Olema Oncology Reports Third Quarter 2025 Financial and Operating Results
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Oncology to Participate in Upcoming Investor Conferences
Olema Oncology to Present Trial-in-Progress Poster for Phase 3 OPERA-02 Trial of Palazestrant Plus Ribociclib at SABCS 2025
Shares of breast cancer therapy developer Olema Pharmaceutical could more than double from here
Olema Oncology Announces New Data from the Phase 1b/2 Trial of Palazestrant Plus Ribociclib in ER+/HER2- Metastatic Breast Cancer at ESMO 2025